L Euller-Ziegler

University of Nice-Sophia Antipolis, Nice, Provence-Alpes-Côte d'Azur, France

Are you L Euller-Ziegler?

Claim your profile

Publications (140)366.4 Total impact

  • Christian Hubert Roux · Liana Euller-Ziegler
    Joint, bone, spine: revue du rhumatisme 10/2015; DOI:10.1016/j.jbspin.2015.04.012 · 2.90 Impact Factor
  • V Breuil · E Fontas · R Chapurlat · P Panaia-Ferrari · H B Yahia · S Faure · L Euller-Ziegler · E Z Amri · P Szulc
    [Show abstract] [Hide abstract]
    ABSTRACT: Oxytocin, a neurohypophysial hormone, regulates bone metabolism in animal studies and postmenopausal women. In men, oxytocin is not associated with bone mineral density, bone turnover markers, or prevalent fractures, but weakly negatively with incident fragility fracture requiring further studies. We previously showed that serum oxytocin (OT) level is associated with bone mineral density (BMD) and bone turnover rate in postmenopausal women. The aim of our study was to assess the relationship between circulating OT levels and bone status in men. In 552 men aged 50 and older from the MINOS cohort, we measured serum levels of OT. We assessed the association of serum OT levels with BMD (lumbar, femoral neck, total hip), bone turnover markers (BTM) (serum N-terminal propeptide of type I procollagen (PINP), bone-specific alkaline phosphatase (bone ALP), and C-terminal telopeptide of type I collagen (CTX-I)) and fracture risk. In the univariate analysis, serum OT level was not associated with BMD at any site, BTM levels, or with prevalent or incident fracture. OT was significantly correlated with body mass index (BMI) (r = 0.17, p < 0.001), total or bioavalaible 17β-estradiol (r = 0.09, p = 0.04 and r = 0.20, p < 0.001, respectively), free testosterone (r = 0.17, p < 0.001), and leptin (r = 0.16, p < 0.001). Multivariate analysis did not show significant relationship between serum OT and BMD. After adjustment for age, BMI, interaction BMI/age, history of fall in the last year, and BMD, OT and prevalent fracture were not associated. By contrast, the same analysis with additional adjustment for prevalent fracture showed a weakly significant negative association between OT and incident fracture, e.g., after adjustment for femoral neck BMD, HR = 0.73, 95 %CI 0.55-0.99, p = 0.04. In men, serum OT levels are not associated with BMD, bone turnover rate, or prevalent fractures. The weak negative relationship with fracture risk requires further studies.
    Osteoporosis International 06/2015; DOI:10.1007/s00198-015-3201-3 · 4.17 Impact Factor
  • Revue du Rhumatisme 03/2015; 82(3). DOI:10.1016/j.rhum.2015.02.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Severe hidradenitis suppurativa (HS), under infliximab, can be associated with different forms of arthritis whose mechanism is unclear. Our objective is to establish the frequency and clinical presentation of new-onset arthritis in HS under infliximab. Severe HS patients under infliximab were followed up between 2007-2012. New articular inflammatory manifestations were investigated by rheumatologist. Three patients over eleven developed a polyarthritis. Mean duration of arthritis was 3 months. At treatment's stop: 2 patients improved and 1 relieved with adalimumab. The inflammatory rheumatism's frequency in HS under infliximab seems underestimated. Copyright © 2015 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
    Joint, bone, spine: revue du rhumatisme 03/2015; DOI:10.1016/j.jbspin.2015.01.020 · 2.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives To evaluate pneumococcal (PV) and influenza (IV) vaccination status in patients (pts) on biotherapies by researching influencing factors. Methods Pts on biotherapies seen between February and July 2013 were questioned about PV and IV status. Variables analysed: age, sex, disease, treatment, immunisation status, reason for non-vaccination and history of pulmonary infection on biotherapy. Percentage comparisons were performed using chi-square and McNemar's tests. Results 594 pts were analysed (406 F + 188 M): 307 rheumatoid arthritis (RA) (51 M +256 F, mean age 59 years); 277 spondyloarthritis (SpA) (135 M +142 F, mean age 48 years); and 10 other diseases. In the RA group, 189 pts were treated with anti-TNFs: 115 with etanercept (Etn); 37 with adalimumab (Ada); 19 with infliximab (Inf); 13 with certolizumab (Cer); and 5 with golimumab (Gol). 118 other pts were treated with another biotherapy, including 42 with rituximab (Rtx); 38 with tocilizumab (To); 24 with abatacept (Aba); and 14 with anakinra (Ana);151 pts had at least 2 biotherapies. One DMARD was combined in 60% and cortisone in 35%. In the SpA group, 271 were treated with anti-TNFs (Ada 121, Etn 85, Inf 46, Gol 14, Cer 5) and 6 with other biotherapies, 86 pts had at least 2 biotherapies. One DMARD was combined in 28% and cortisone in 5%. The 2012-2013 winter IV (recommended for 37% by the general practitioner [GP]; 45% for RA and 28% for SpA), and in 63% after age 65, and in 79% by the rheumatologist (including 82% for RA and 75% for SpA, and in 93% after age 65) was given to 260 pts (43.77%; including 44% for RA and 43% for SpA and in 62% of pts >65 years). Pts having refused were 47%, (55% were RA and 39% were SpA), generally because of fear (45% RA and 32% SpA). PV over the last 5 years (recommended in 14% by the GP, including 16% for RA and 12% for SpA, and in 24% after age 65, and in 78% by the rheumatologist in RA and SpA, and in 86% after age 65) had been done for 370 pts (62.29%; including 60% in RA and 65% in SpA, and in 70% over age 65). Pts having refused were 25% (31% RA and 17% SpA). In total, 37% had two vaccinations (53% after age 65): 33% one of two; 30% neither of the two. 67 pts (48 RA) had an infection (11%), including 20 hospitalisations. Variables selected for a better vaccination: a prior IV; the recommendation by the GP and the rheumatologist (p<0.001); age >65 years (IV p<0.001, PV p=0.02). The other parameters were not influencing (type and number of biotherapies, DMARDs, cortisone, disease). Infections were not lower in those vaccinated compared to those non-vaccinated (number of pts too low). The PV was up-to-date more frequently than the IV (p<0.001) in the two diseases. Fear of side effects was one of the causes of non-vaccination. Conclusions The rate of IV was 44% compared to 62% for PV. Age influences the vaccination status, as well as the information given to the patient. This should be repeated with pts and physicians in order to improve protection. Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.1935
    Annals of the Rheumatic Diseases 06/2014; 73(Suppl 2):285-286. DOI:10.1136/annrheumdis-2014-eular.1935 · 10.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Few data have been published about the diagnostic value of standard AP view and Schuss X rays association Objectives Our objective is to compare the contribution to diagnosis of the association standard AP view and Schuss X rays versus the single Schuss X ray. Methods Studied population: From 2007 to 2009, a general population, two-phase study was conducted in 6 French centers to estimate the prevalence of knee and/or hip OA gather a cohort which included only patients with Kellgren Laurence (KL) ≥2 (KHOALA (1)). During this prevalence study we obtained X-rays from 3707 subjects aged 40 to 75 years old. For the current work, we selected the first 304 participants regardless of their stage. X-rays reading: A first reading of standard AP + Schuss views was carried out by an expert rheumatologist (BM), and then a second reading of Schuss X-rays only was carried out remotely (blinded to the results of the first lecture), by the same examiner. Delay between the two readings was 2 years. Analysis focused on the comparison of KL stage of each knee, as well as on osteophytes detection and localization (Medial Condyle (MC), Lateral (LC), Medial Tibial Plateau (MTP) or Lateral (LTP) ranked from 0 to 3), Joint space narrowing (JSN) (ranked from 0 to 4) and bone sclerosis (MC, LC, MTP, LTP). Results Mean age was 58 years (8.6), Body Mass Index (BMI) was 29.8 (5.4). Comparison of 2 readings showed a significantly higher proportion of patients with a KL ≥2 with the two X-ray combined (right knee: p<0.0001; left knee: p<0.0003). In contrast, a finer analysis taking into account JSN (respectively p=0.8 and 0.07), osteophytes (0.8 and 0.3), and bone condensation (0.6 and 0.6) didn't show any significant differences. Our data suggested a less value of Schuss X-ray alone when BMI is high. A comparison of Schuss versus standard AP X-rays alone showed a Schuss superiority to detect JSN and osteophytes (p=0.0001 and p=0.0001). Conclusions Combined procedure detect more radiological OA than Schuss X ray alone. However, when assessing separately the two main features of OA (JSN and osteophytes), no significant difference appeared in spite of a trend favouring the combined procedure. The partly subjective global KL scoring system is probably more robust to detect OA than separated assessment of JSN and osteophytes alone.Finally, regarding higher cost and irradiation of both radiographs compared to schuss alone, the choice of the procedure will depend on the aim of the study: in epidemiological studies only schuss may be realised, while in a clinical diagnosis perspective both views should be recommended. References Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.3477
    Annals of the Rheumatic Diseases 06/2014; 73(Suppl 2):250-250. DOI:10.1136/annrheumdis-2014-eular.3477 · 10.38 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: sec> Objectives Rheumatoid arthritis (RA) patients are at an increased risk of developing comorbid conditions. A close monitoring of the disease targeting a status of low disease activity is associated with a better outcome. The aim of this trial was to evaluate the impact of a nurse-led programme on comorbidities and the impact of patient self-assessment of disease activity on the management of RA. Methods We enrolled 970 patients (mean age 58&emsp14;years, 79% women) in a prospective, randomised, controlled, open-label, 6-month trial. In the comorbidity group (n=482), the nurse checked comorbidities and sent the programme results to the attending physicians. In the self-assessment group (n=488), the nurse taught the patient how to calculate his/her Disease Activity Score which had to be reported on a booklet to be shared with the treating rheumatologist. The number of measures taken for comorbidities and the percentage of patients recording a change (initiation, switch or increased dose) in disease-modifying antirheumatic drugs (DMARDs) in the 6&emsp14;months follow-up period of the study defined the outcomes of the trial. Results The number of measures taken per patient was statistically higher in the comorbidity group: 4.54±2.08 versus 2.65±1.57 (p<0.001); incidence rate ratio: 1.78 (1.61–1.96) and DMARD therapy was changed more frequently in the self-assessment group: 17.2% versus 10.9% (OR=1.70 (1.17; 2.49), p=0.006). Conclusions This study demonstrates the short-term benefit of a nurse-led programme on RA comorbidity management and the impact of patient self-assessment of disease activity on RA treatment intensification. Trial registration number NCT #01315652. </sec
    Annals of the Rheumatic Diseases 05/2014; 72(Suppl 3). DOI:10.1136/annrheumdis-2013-204733 · 10.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Patients with RA are at an increased risk of developing a number of co-morbid conditions which have a major influence on both mortality and the outcome of RA. Objectives To evaluate the impact of a nurse led program on the management of comorbidities (cardiovascular diseases (CVD), infection, cancer and osteoporosis) in RA. Methods Study design: Prospective, randomized controlled open, 6-month trial (NCT #0131652). Patients: RA (ACR 1987 criteria). Study treatment: Collection of data by the nurse at a specific out-patient clinic for the four studied RA comorbidities according to the recommendations of the French Society of Rheumatology. In the event of non-agreement with the recommendation the patient was informed. A report summarizing the results of this program prepared by the nurse was sent to the patient’s attending physician and rheumatologist. Treatment allocation: After written informed consent, the study treatment was allocated randomly (i.e. either this evaluation of comorbidities or an evaluation of a self assessment program (not reported here). Outcome variables: number of actions undertaken against comorbidities according to the recommendations during the 6 months following this program. Actions taken into account for CVD were : introduction of lipid-lowering therapy or anti-platelet therapy, smoking cessation, taking of blood pressure, purchase of a sphygmomanometer, weight loss; for infections: pneumococcal, influenza, hepatitis and meningococcal vaccinations ; for cancers : mammography, Pap smears, consultation with an urologist, fecal occult blood testing, colonoscopy, consultation with a dermatologist; for osteoporosis: dual-Energy X-ray absorptiometry, increased alimentary calcium uptake, introduction of calcium and/or vitamin D supplementation and/or an osteoporotic medication. Results There was no difference in the baseline characteristics of the 970 recruited patients (488 and 482 in the active and control groups, respectively): Age: 58±11 years, female gender: 79%, disease duration: 11[6.2-19.1] y, history or current biotherapy, DAS28: 3.1 ± 1.3., mHAQ: 0.25 (0.00-0.62). During the 6-month follow-up period, the number of actions per patient was statistically higher in the group comorbidities : 4.54 ± 2.08 vs 2.65 ± 1.57 (p< 0.001); Incidence Rate Ratio(IRR): 1.78 [1.60 -1.83]. This increase concerned CVD (IRR: 1.44 [1.30-1.61]), infections (IRR 1.78 [1.45 – 2.19]), cancer (IRR: 1.65 [1.42 – 1.92]) and osteoporosis (IRR 3.43 [2.88 – 4.13]). Conclusions This study demonstrates the short-term benefit of a nurse led program on the management of comorbidities. Longer term follow-up of patients is required to better evaluate the sustainability of this benefit. Acknowledgements This study was conducted thanks to a grant from the French National Research Program (PHRC) and thanks to an unrestricted grant from Roche Ltd France Disclosure of Interest None Declared
    Annals of the Rheumatic Diseases 01/2014; 72(Suppl 3):A131-A131. DOI:10.1136/annrheumdis-2013-eular.439 · 10.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To estimate the prevalence of ultrasonographic enthesitis in psoriasis patients with or without musculoskeletal symptoms and to investigate their evolution under systemic treatments given for the cutaneous symptoms. Prospective bi-centre (rheumatology and dermatology) study over 6months, including psoriasis pts requiring systemic treatment, with or without musculoskeletal symptoms and/or psoriatic arthritis (PsA). Clinical assessment (M0 and M6) included: BASDAI, HAQ, SPARCC, PASI and nail disease. US assessment (M0 and M6) with Grey Scale and PD of 10 entheses was performed by one trained rheumatologist blinded to clinical and biological data, scoring morphological, structural lesions and PD signal. Complete data were obtained on 340 entheses in 34 patients. Twenty-two were asymptomatic (PsO) and 12 symptomatic (PsA). They received conventional treatment and/or biologics. US abnormalities were found in 97.1% total population and in 86.4% PsO patients. 95/340 enthesitis were observed, 57/220 in PsO vs 38/120 in PsA (P=0.258). Neither group had PD signal. Presence of 24/90 enthesitis in patients with nail disease vs 33/130 without (P=0.831). AT M6: Twenty-three patients were assessed. US morphological (thickness and hypoechogenicity) abnormalities were improved in PsO (n=13) (P=0.021) and PsA patients (n=10) (P=0.164) with a significant decrease of BASDAI, HAQ, SPARCC. We observed a high frequency of US enthesitis in psoriasis patients, with or without musculoskeletal symptoms, requiring systemic treatment. At 6months, US morphological abnormalities were likely to improve. Further studies would be interesting to validate our data and to assess their potential impact on PsA development. Copyright © 2015 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
    Annals of the Rheumatic Diseases 01/2014; 72(Suppl 3):A541-A541. DOI:10.1136/annrheumdis-2013-eular.1619 · 10.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Oxytocin (OT), a neurohypophysial hormone regulated by estrogen and leptin, may play a role in bone metabolism in humans as suggested by animal studies. This study assessed the relationship between OT and bone status in a large population of postmenopausal women. Subjects and methods: Subjects were included in the Osteoporosis and Ultrasound study, a 6-year prospective study in a population-based cohort. Final visit data were used for this cross-sectional study. OT, leptin, and estradiol serum levels were measured in 1097 postmenopausal women and compared with bone mineral density (BMD), fractures, and the bone turnover markers (BTMs) procollagen type 1 N-terminal propeptide, bone alkaline phosphatase, and C-telopeptide of type 1 collagen. Results: The median age was 70.8 years, 16% were osteoporotic, 48% were osteopenic, and 29% had at least one fracture. The OT serum level was related to spine (r = +0.12, P = .0002) and total hip BMD (r = +0.21, P < .0001) and with BTM (procollagen type 1 N-terminal propeptide: r = -0.13, P < .0001, bone alkaline phosphatase: r = -0.07, P = .02, C-telopeptide of type 1 collagen: r = -0.18, P < .0001). The relationship of OT with BMD was independent of BTM. After adjustment for confounding factors, the correlation between OT serum level and BMD remains significant at the hip in women with unmeasurable estradiol or leptin above the median value. There was no significant relationship between OT serum levels and fractures. Conclusion: High OT levels are associated with high BMD, especially at the hip in women with low estradiol or high leptin serum levels. The mechanism may be explained by the effect of OT on bone turnover.
    The Journal of Clinical Endocrinology and Metabolism 01/2014; 99(4):jc20134126. DOI:10.1210/jc.2013-4126 · 6.21 Impact Factor
  • Annales de Dermatologie et de Vénéréologie 12/2013; 140(12):S554-S555. DOI:10.1016/j.annder.2013.09.435 · 0.92 Impact Factor
  • Annales de Dermatologie et de Vénéréologie 12/2013; 140(12):S506. DOI:10.1016/j.annder.2013.09.327 · 0.92 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chondrogenesis has been widely investigated in vitro using bone marrow-derived mesenchymal stromal cells (BM-MSCs) or primary chondrocytes. However, their use raises some issues partially circumvented by the availability of Adipose tissue-derived MSCs. Herein; we characterized the chondrogenic potential of human Multipotent Adipose-Derived Stem (hMADS) cells, and their potential use as pharmacological tool. hMADS cells are able to synthesize matrix proteins including COMP, Aggrecan and type II Collagen. Furthermore, hMADS cells express BMP receptors in a similar manner to BM-MSC, and BMP6 treatment of differentiated cells prevents expression of the hypertrophic marker type X Collagen. We tested whether IL-1β and nicotine could impact chondrocyte differentiation. As expected, IL-1β induced ADAMTS-4 gene expression and modulated negatively chondrogenesis while these effects were reverted in the presence of the IL-1 receptor antagonist. Nicotine, at concentrations similar to those observed in blood of smokers, exhibited a dose dependent increase of Aggrecan expression, suggesting an unexpected protective effect of the drug under these conditions. Therefore, hMADS cells represent a valuable tool for the analysis of in vitro chondrocyte differentiation and to screen for potentially interesting pharmacological drugs.
    Biochemical and Biophysical Research Communications 10/2013; 440(4). DOI:10.1016/j.bbrc.2013.10.012 · 2.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Several markers of comorbidities and cardiovascular (CV) risk are disturbed in moderate to severe psoriasis (PsO). The effect of systemic treatments of psoriasis on these markers remains poorly understood. To study the frequency of disturbance of inflammatory parameters and markers of comorbidities and CV risk associated with moderate to severe PsO and psoriatic arthritis (PsA), and to assess their evolution under systemic treatments. Monocentric prospective study on patients with PsO and PsA starting a systemic treatment for their psoriasis. The following markers were evaluated at baseline (M0), 3 months (M3) and 6 months (M6); weight, fasting blood glucose, blood pressure, uric acid, hepatic steatosis, smoking, lipid, metabolic and inflammatory parameters. Forty-three patients, 31 PsO and 12 PsA, were included. Forty completed the study. Response to treatment was good, with 71% of the population obtaining a Psoriasis Area and Severity Index (PASI) of 75. All patients had at least one comorbidity, and 45% had two or more. A statistically significant decrease was observed only for inflammatory parameters (C-reactive protein [CRP], P = 0.004) and erythrocyte sedimentation rate (ESR, P = 0.002). We did not observe any correlation between the PASI and CRP (correlation coefficient 0.128, P = 0.438) or ESR (correlation coefficient 0.294, P = 0.069) for responding patients. We observed a high frequency of disturbance of inflammatory parameters and markers of comorbidities and CV risk in a population with moderate to severe PsO and PsA, most of which were not detected before. A significant decrease in inflammatory parameters was noted after the introduction of systemic therapy, while other parameters remained unaffected by the treatment, except the weight that increased under biologics therapies.
    Journal of the European Academy of Dermatology and Venereology 08/2013; 28(9). DOI:10.1111/jdv.12255 · 2.83 Impact Factor
  • Véronique Breuil · Liana Euller-Ziegler
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporosis is particularly frequent in subjects suffering from chronic obstructive pulmonary disease (COPD) and asthma, because they share numerous common risk factors: aging (for COPD), smoking, vitamin D deficiency, inactivity, muscular weakness, systemic inflammation, are an integral part of the physiopathology of COPD and asthma. Oral corticosteroid used in the severe forms of COPD and asthma contribute to the risk of osteoporosis in these frail patients and the application of the guidelines for steroid-induced osteoporosis is crucial. Inhaled corticosteroid, basis of asthma treatment and also used in some forms of COPD, has a less clear impact on bone status; however recent publications are in favour of a moderate effect, but long-term studies are necessary at these patients with long term treatments. Finally, severe kyphosis related to multiple vertebral ribs and sternal fractures can contribute to an alteration of respiratory function. The management of these patients is based on a global evaluation of fracture risk including the risk factors of osteoporosis and the measure bone mineral density, the non pharmacological measures of the osteoporosis treatment, vitamin D supplementation often required and, if needed, specific drugs of osteoporosis. This review emphasizes the need to increase vigilance of practitioners about the risk of osteoporosis in COPD and asthma.
    Revue du Rhumatisme Monographies 04/2013; 80(2):136–140. DOI:10.1016/j.monrhu.2013.01.002
  • Christian H Roux · Rodolphe Anty · Stephanie Patouraux · Liana Euller-Ziegler
    The Journal of Rheumatology 01/2013; 40(1):99. DOI:10.3899/jrheum.120599 · 3.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectifs Cette étude visait à décrire la prévalence de l’arthrose du genou ou de la hanche, l’histoire naturelle de la maladie, ainsi que les facteurs pronostiques de son développement et les éléments déterminant le coût et l’accès aux soins pour une cohorte de patients en France. Méthodes Les sujets âgés de 40 à 75 ans, souffrant d’arthrose symptomatique du genou et/ou de la hanche uni- ou bilatérales (confirmées par les critères de l’ACR), au stade 2 ou supérieur dans la classification de Kellgren & Lawrence (KL), ont été recrutés à partir d’une enquête de prévalence en population générale pour constituer la cohorte multicentrique KHOALA. Les données de base collectées incluaient les données sociodémographiques et cliniques ; les scores WOMAC, IKS et Harris pour la douleur et la fonction ; le score MAQ pour l’activité physique ; l’index de comorbidité fonctionnelle ; le score GHQ28 pour le statut psychologique ; et les scores SF-36 (générique) et OAKHQOL (spécifique) pour l’évaluation de la qualité de vie. Des échantillons de sang et d’urine ont été collectés. Résultats Huit-cent-soixante-dix-huit personnes ont été incluses, 222 atteintes d’arthrose de la hanche (âge moyen 61,2 ± 8,8 ans), 607 atteintes d’arthrose du genou (âge moyen 62,0 ± 8,5 ans) et 49 atteintes d’arthrose de la hanche et du genou (âge moyen 64,9 ± 7,9 ans). L’indice de masse corporelle (IMC) moyen était de 26,9 ± 4,5 pour les arthroses de la hanche et de 30,3 ± 6,3 pour les arthroses du genou. Les patients souffrant d’arthrose de la hanche et du genou avaient respectivement des index de comorbidité moyens de 1,99 et 2,06. La sévérité radiographique de la maladie pour des stades 2, 3 et 4 dans la classification de KL étaient, respectivement, de 69,8 %, 26,1 % et 4,1 % pour les arthroses de la hanche, et de 44,5 %, 30,3 %, et 25,2 % pour les arthroses du genou. En comparaison avec la population générale, les scores SF-36 standardisés selon l’âge et le sexe étaient fortement diminués pour les arthroses du genou et de la hanche dans toutes ses dimensions, particulièrement dans les dimensions physiques et émotionnelles. Perspectives Les patients vont être suivis annuellement, tour à tour par courrier et par une visite clinique. Cette cohorte, représentative de patients souffrant d’arthrose du genou et de la hanche, va être une opportunité pour de futures recherches collaboratives.
    Revue du Rhumatisme 01/2013; 80(1):32–39. DOI:10.1016/j.rhum.2012.11.004
  • Véronique Breuil · Liana Euller-Ziegler
    [Show abstract] [Hide abstract]
    ABSTRACT: Phosphated diabetes are rare diseases, characterized by renal phosphate wasting, which results in hypophosphatemia, bone demineralization and osteomalacia. We review the pathophysiology of phosphate metabolism, revolutionized by the discovery of phosphatonines, particularly the FGF23, which sheds a new light on the various etiologies which are detailed: tumor-induced osteomalacia, genetic phosphate diabetes (X-linked hypophosphatemia, autosomal-dominant hypophosphatemic rickets, autosomal-recessive hypophosphatemic rickets, hypophosphatemic rickets with hypercalciuria, hypophosphatemia with nephrolithiasis by mutation of NPT2A and NHERF1), hyperparathyroidism, Fanconi syndrome and drug-induced phosphated diabetes. Diagnostic tools, improved by FGF23 dosage and treatment are also discussed.
    Revue du Rhumatisme Monographies 09/2012; 79(4):253–257. DOI:10.1016/j.monrhu.2012.04.010
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: This study aimed to describe the prevalence of symptomatic knee and hip osteoarthritis (OA) and its course over time, as well as identify prognostic factors of OA course and determinants of costs and access to care in France in a patient cohort. Methods: Subjects aged 40 to 75 years, with uni- or bilateral symptomatic hip and/or knee OA (ACR criteria), Kellgren and Lawrence (KL) stage 2 or greater, were recruited from a French national prevalence survey for the multicenter KHOALA cohort study. Data collected at baseline included sociodemographic and clinical data; WOMAC, IKS and Harris scores for pain and function; MAQ score for physical activity; functional comorbidity index; GHQ28 score for psychological status; and SF-36 (generic) and OAKHQOL (specific) scores for quality of life. Blood and urine samples were collected. Results: Eight hundred and seventy-eight subjects were included, 222 with OA of the hip (mean age 61.2±8.8 years), 607 knee (mean age 62.0±8.5 years) and 49 both hip and knee (mean age 64.9±7.9 years). Mean body mass index was 26.9±4.5 for hip OA and 30.3±6.3 for knee OA. Hip and knee OA patients had 1.99 and 2.06 comorbidities, on average, respectively. Disease severity on X-rays for KL stages 2, 3 and 4 for hip OA was 69.8, 26.1 and 4.1%, respectively, and for knee OA, 44.5, 30.3, and 25.2%. As compared with population norms, age- and sex-standardized SF-36 scores were greatly decreased for both knee and hip OA in all dimensions, particularly physical and emotional dimensions. Perspectives: Patients will be followed up annually, alternately by mail and clinical visit. This cohort of representative patients with knee and hip OA will be an opportunity for future collaborative research.
    Joint, bone, spine: revue du rhumatisme 06/2012; 79(6). DOI:10.1016/j.jbspin.2012.03.011 · 2.90 Impact Factor
  • Annals of the rheumatic diseases 04/2012; 71(8):1429-31. DOI:10.1136/annrheumdis-2011-200915 · 10.38 Impact Factor

Publication Stats

2k Citations
366.40 Total Impact Points


  • 2009–2014
    • University of Nice-Sophia Antipolis
      • Faculty of medicine
      Nice, Provence-Alpes-Côte d'Azur, France
  • 2011
    • Centre Hospitalier Universitaire de Nancy
      Nancy, Lorraine, France
  • 1990–2008
    • Centre Hospitalier Universitaire de Nice
      Nice, Provence-Alpes-Côte d'Azur, France
  • 2006
    • Hôpital Cochin (Hôpitaux Universitaires Paris Centre)
      Lutetia Parisorum, Île-de-France, France
  • 1989
    • Centre Antoine-Lacassagne
      Nice, Provence-Alpes-Côte d'Azur, France